Summary:
FDA marketing rules draw a clear line: you sell the benefit, but you don’t rewrite the label. Product names, taglines, and claims all signal “intended use,” and reviewers read between every line. Teams that anchor copy to approved language, build an internal claim grid, and pressure-test campaigns before launch protect both revenue and reputation.
In the 80s and 90s, pharmaceutical brand names tried to tell a story. Ozobax, a formulation of baclofen, sounded a lot like “back,” and it treated conditions closely linked to back pain. The link between name and use felt almost like a wink from the marketing team.
Fast-forward to today, and you get products like Mounjaro. The name gives no clue that it treats type 2 diabetes or that prescribers also reach for it in weight-related care. That shift didn’t happen by accident. Inside FDA, reviewers spar over how close a name or claim can sit to real-world use. Outcomes often depend on which desk your file lands on.
What FDA Actually Polices in Promotion
The FDA polices “intended use” and “misbranding.” If your copy, visuals, or brand name imply a use beyond the approved label, you hand FDA a reason to act. Even a clever metaphor can function as a claim.
The approved label should work more like your ceiling rather than a suggestion. Indications, limitations, and risk language set the outer edge of what your ads can imply. If your team wants to move beyond that edge, you’re in off-label territory. At that point, your risk profile shifts from “bold campaign” to “regulatory exhibit.”
Building Promotional Materials That Still Sell
Marketing teams that thrive under FDA oversight tend to build structure around creativity thanks to their legal team. One common tool is a claim matrix that links each proposed statement to a citation and any required risk language. That matrix then shapes what agencies pitch and what sales teams repeat.
Visuals and taglines receive similar treatment. A dramatic “before and after” weight-loss image or a line suggesting a cure is often reviewed as a claim. Teams frequently route these through the same internal process as body copy so that campaigns tell a consistent, supportable story.
Before You Hit Publish, Phone a Friend
FDA enforcement letters target patterns. Once a theme appears across your website, social feeds, and sales aids, it becomes evidence of intended use. Before a new campaign rolls out, bring in outside counsel with deep regulatory review experience.
Baker Jenner works with companies that want to move product without inviting regulators to the party. To talk through compliance and how it can be incorporated into your business plans, call (404) 400-5955.
Pharmaceutical Naming FAQ
Can my product name hint at what it does?
Not safely. Names that echo disease states, body parts, or outcomes can signal intended use. Treat naming like any other claim and run it through regulatory and legal review before brand development hardens.
Are lifestyle images and taglines treated as claims?
Yes. A photo of dramatic weight loss or a tagline that implies a cure or reversal can function as implied claims. Tie imagery and slogans back to outcomes supported by your data and balanced by appropriate risk information.
Can I mention off-label research in marketing materials?
Promotional pieces should align with the approved label. Off-label discussion belongs in tightly controlled scientific exchange, not sales collateral aimed at customers or consumers. When in doubt, keep promotional assets squarely within approved uses and seek tailored legal guidance.
Baker Jenner LLLP
